Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130362 · ClinicalTrials.gov registry record
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
A clinical trial of Crohn's Disease, sponsored by AbbVie.
- Active
- Registry status
- 1,446
- Enrollment target
- 20
- Study locations
NCT02130362 is a study of Crohn's Disease that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 1,446 participants, below the 2,381-participant average among 105 other Crohn's Disease trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02130362, a study of Crohn's Disease, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- 1,446 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
Conditions Studied
Study Locations (20)
California
- Children's Hospital Los Angeles /ID# 141551 - Los Angeles
- Private practice: Dr. Shervin Rabizadeh /ID# 137269 - Los Angeles
- Rady Children's Hospital San Diego /ID# 140883 - San Diego
- Univ California, San Francisco /ID# 141312 - San Francisco
Massachusetts
- Tufts Medical Center /ID# 143581 - Boston
- Massachusetts General Hospital /ID# 141552 - Boston
- Boston Children's Hospital /ID# 164102 - Boston
- Duplicate_UMass Chan Medical School /ID# 148325 - Worcester
Alabama
- Univ Alabama, Birmingham CCC /ID# 146060 - Birmingham
- University of South Alabama /ID# 137255 - Mobile
Connecticut
- Connecticut Children's Medical Center - Hartford /ID# 137265 - Hartford
- Yale University School of Medicine /ID# 137257 - New Haven
Florida
- Nemours Children's Health System /ID# 148498 - Jacksonville
- University of Miami /ID# 140893 - Miami
Georgia
- Winship Cancer Institute of Emory University /ID# 144274 - Atlanta
- Children's Ctr Digestive, US /ID# 144625 - Atlanta
Arizona
- Phoenix Children's Hospital /ID# 141336 - Phoenix
Colorado
- Children's Hospital Colorado - Aurora /ID# 137261 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,446 participants |
| Start Date | 2014-08-28 |
| Est. Completion | 2030-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02130362
The ClinicalTrials.gov registry entry for NCT02130362 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,446 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,381-participant average among 105 other Crohn's Disease trials with a reported enrollment target (39% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02130362 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Massachusetts, Alabama.
Frequently Asked Questions
What is clinical trial NCT02130362 about?
NCT02130362 is a clinical study titled "A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)". This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
What is the current status of trial NCT02130362?
This trial is currently active not recruiting. The enrollment target is 1,446 participants. The study started on 2014-08-28. Estimated completion is 2030-11.
What conditions does trial NCT02130362 study?
This clinical trial studies the following conditions: Crohn's Disease.
Who is sponsoring clinical trial NCT02130362?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02130362 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
RECRUITING · NA
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Behavioral Therapy for Crohn's Disease
RECRUITING · NA
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RECRUITING · Phase 4
-
Helmsley 3.0: Abbreviated MRE
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.